GlucoTrack Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
GCTK$1.39-32.2%Stored close · as of Oct 29, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
Financial Statements
The financial statements of the Company filed herewith are set forth in Part II, Item 8 of this report.
Exhibit Index
| Exhibit Number | Description |
| 2.1 | Merger Agreement and Plan of Reorganization, dated as of May 25, 2010, by and among Integrity Applications, Inc., Integrity Acquisition Ltd. and A.D. Integrity Applications Ltd. (1) |
| 3.1 | Certificate of Incorporation of Integrity Applications, Inc. (1) |
| 3.2 | Certificate of Amendment to Certificate of Incorporation of Integrity Applications, Inc. (1) |
| 3.3 | Bylaws of Integrity Applications, Inc. (1) |
| 3.4 | Certificate of Amendment to Certificate of Incorporation of Integrity Applications, Inc. (16) |
| 3.5 | Amendments to The Company’s Certificate of Incorporation ** |
| 4.1 | Specimen Certificate Evidencing Shares of Common Stock (1) |
| 4.2 | Form of Common Stock Purchase Warrant (1) |
| 4.3 | Form of Series A Securities Purchase Agreement (2) |
| 4.4 | Form of Series A Common Stock Purchase Warrant (2) |
| 4.5 | Form of Series A Registration Rights Agreement (2) |
| 4.6 | Certificate of Designation of Preferences and Rights of Series A 5% Convertible Preferred Stock (2) |
| 4.7 | Form of Series B Securities Purchase Agreement (3) |
| 4.8 | Form of Series B-1 Common Stock Purchase Warrant (3) |
| 4.9 | Form of Series B-2 Common Stock Purchase Warrant (3) |
| 4.10 | Form of Series B Registration Rights Agreement (3) |
| 4.11 | Certificate of Designation of Preferences and Rights of Series B 5.5% Convertible Preferred Stock (3) |
| 4.12 | Form of Series C Securities Purchase Agreement (6) |
| 4.13 | Form of Series C-1 Common Stock Purchase Warrant (6) |
| 4.14 | Form of Series C-2 Common Stock Purchase Warrant (6) |
| 4.15 | Form of Series C Registration Rights Agreement (6) |
| 4.16 | Certificate of Designation of Preferences and Rights of Series C 5.5% Convertible Preferred Stock (6) |
| 4.17 | Form of Series D Securities Purchase Agreement (10) |
| 4.18 | Form of Series D-1 Common Stock Purchase Warrant (10) |
| 4.19 | Form of Series D-2 Common Stock Purchase Warrant (10) |
| 4.20 | Form of Series D-3 Common Stock Purchase Warrant (10) |
| 4.21 | Form of Series D Registration Rights Agreement (10) |
| 4.22 | Form of Prefunded Warrant (12) |
| 10.1* | Integrity Applications, Inc. 2010 Incentive Compensation Plan (1) |
| 10.2* | Amendment No. 1 to Integrity Applications, Inc. 2010 Incentive Compensation Plan (11) |
| 10.3* | Amendment No. 2 to Integrity Applications, Inc. 2010 Incentive Compensation Plan (9) |
| 10.4* | Form of Director and Officer Indemnification Agreement (1) |
| 10.5* | Personal Employment Agreement, dated as of October 19, 2010, between A.D. Integrity Applications Ltd. and Avner Gal (1) |
| 10.6* | Letter Agreement, effective as of April 7, 2017, among Integrity Applications, Inc., A.D. Integrity Applications Ltd., and Avner Gal (9) |
| 10.7* | Amended and Restated Personal Employment Agreement, effective as of April 7, 2017, between A.D. Integrity Applications Ltd. and David Malka (9) |
| 10.8 | Irrevocable Undertaking of Indemnification, dated as of July 26, 2010, by and among Integrity Applications, Inc., Avner Gal, Zvi Cohen, Ilana Freger, David Malka and Alexander Raykhman (1) |
| 10.9 | Investment Agreement, dated February 18, 2003, between A.D. Integrity Applications Ltd., Avner Gal, Zvi Cohen, David Freger and David Malka and Yigal Dimri (1) |
| 10.10* | Form of Stock Option Agreement (1) |
| 10.11* | Form of Stock Option Agreement (ESOP) (1) |
| 10.12 | Letter of Approval, addressed to Integrity Applications Ltd. from the Ministry of Industry, Trade and Employment of the State of Israel (5) |
| 10.13 | Letter of Undertaking, addressed to the Ministry of Industry, Trade and Employment of the State of Israel – Office of the Chief Scientist from Integrity Applications Ltd. (4) |
| 10.14 | Investment Agreement, dated March 16, 2004, by and among A.D. Integrity Applications Ltd., Yitzhak Fisher, Asher Kugler and Nir Tarlovsky. (4) |
| 10.15 | Form of Underwriting Agreement, dated April 13, 2023, between GlucoTrack, Inc. and Aegis Capital Corp. (12) |
| 10.16* | Consulting Agreement, dated October 11, 2023, by and between GlucoTrack, Inc. and James S. Cardwell (13) |
| 10.17 | Form of Exchange Agreement, dated February 13, 2024, by and among GlucoTrack, Inc. and certain holders thereof (14) |
| 10.18* | Consulting Agreement, dated August 1, 2019, by and between Integrity Applications, Inc. and Jolie Kahn (15) |
| 10.19* | Employment Agreement, dated October 19, 2021, by and between Integrity Applications, Inc. and Paul V. Goode (17) |
| 14.1 | Code of Ethics (7) |
| 19 | Insider Trading Policies and Procedures, adopted March 22, 2024.*** |
| 21.1 | Subsidiaries of Integrity Applications, Inc. (8) |
| 23.1 | Consent of Grant Thornton Israel |
| 31.1 | Certification of Principal Executive Officer Pursuant to Exchange Act Rule 13a-14(a) or 15(d)-14(a), as Adopted Pursuant to Section 302 of the Sarbanes Oxley Act of 2002 *** |
| 31.2 | Certification of Principal Financial Officer Pursuant to Exchange Act Rule 13a-14(a) or 15(d)-14(a), as Adopted Pursuant to Section 302 of the Sarbanes Oxley Act of 2002 *** |
| 32.1 | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes Oxley Act of 2002 *** |
| 32.2 | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes Oxley Act of 2002 *** |
| 97.1 | Policy Related to Recovery of Erroneously Awarded Compensation, adopted November 30, 2023.*** |
| 101.INS | Inline XBRL Instance Document * |
| 101.SCH | Inline XBRL Schema Document * |
| 101.CAL | Inline XBRL Calculation Linkbase Document * |
| 101.DEF | Inline XBRL Taxonomy Extension Calculation Linkbase * |
| 101.LAB | Inline XBRL Label Linkbase Document * |
| 101.PRE | Inline PRE XBRL Presentation Linkbase Document * |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| (1) | Previously filed as an exhibit to the Company’s Registration Statement on Form S-1, as filed with the SEC on August 22, 2011. |
| (2) | Previously filed as an exhibit to the Company’s Current Report on Form 8-K, as filed with the SEC on March 18, 2013. |
| (3) | Previously filed as an exhibit to the Company’s Current Report on Form 8-K, as filed with the SEC on September 5, 2014. |
| (4) | Previously filed as an exhibit to Amendment No. 1 to the Company’s Registration Statement on Form S-1, as filed with the SEC on October 7, 2011. |
| (5) | Previously filed as an exhibit to Amendment No. 3 to the Company’s Registration Statement on Form S-1, as filed with the SEC on November 10, 2011. |
| (6) | Previously filed as an exhibit to the Company’s Current Report on Form 8-K, as filed with the SEC on April 14, 2016. |
| (7) | Previously filed as an exhibit to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016, as filed with the SEC on March 31, 2017. |
| (8) | Previously filed as an exhibit to the Company’s Registration Statement on Form S-1, as filed with the SEC on November 7, 2017. |
| (9) | Previously filed as an exhibit to the Company’s Current Report on Form 8-K, as filed with the SEC on April 15, 2017 |
| (10) | Previously filed as an exhibit to the Company’s Current Report on Form 8-K, as filed with the SEC on March 7, 2018. |
| (11) | Previously filed as an exhibit to the Company’s Current Report on Form 8-K, as filed with the SEC on March 23, 2016. |
| (12) | Previously filed as an exhibit to the Company’s Current Report on Form 8-K, as filed with the SEC on April 17, 2023. |
| (13) | Previously filed as an exhibit to the Company’s Current Report on Form 8-K, as filed with the SEC on October 12, 2023. |
| (14) | Previously filed as an exhibit to the Company’s Current Report on Form 8-K, as filed with the SEC on February 16, 2024. |
| (15) | Previously filed as an exhibit to the Company’s Current Report on Form 8-K, as filed with the SEC on August 8, 2019. |
| (16) | Previously filed as an exhibit to the Company’s Current Report on Form 8-K, as filed with the SEC on April 23, 2020. |
| (17) | Previously filed as an exhibit to the Company’s Current Report on Form 8-K, as filed with the SEC on October 25, 2021. |
| * | Compensation Plan or Arrangement or Management Contract. |
| ** | Previously filed. |
| *** | Filed herewith. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.